Digital & Innovation
ADG at forefront of emerging trend in online clinical communities
Digital & Innovation: In an Australian medical publisher first, AusDoc launched a new social-media style communities on its platform that allows doctors and specialists to join therapy-area related groups in a safe and secure online environment.
Australian Doctor Group’s editor-in-chief, Jo Hartley, joined Health Industry Hub to discuss the clinician gap that AusDoc Groups is addressing and why a more integrated medical community is important to bettering patient outcomes.
On AusDoc doctors can now connect to share deidentified patient cases and discuss hot topics. They will be able post their thoughts, questions and images within AusDoc’s secure platform where only other doctors will be able to see what they post.
The initial AusDoc Groups launch includes two groups for doctors to join, each chaired by specialists in their field: medicolegal and dermatology.
Cardiology and women’s health groups are also planned for launched in the coming weeks.
News & Trends - MedTech & Diagnostics
Health insurers clash with government on GUIs decision, prompting threat of premium hikes
MedTech & Diagnostics News: A warning of potential increases in health insurance premiums for 15 million Australians has been issued […]
MoreNews & Trends - MedTech & Diagnostics
Catheter ablation underused in atrial fibrillation despite proven efficacy
MedTech & Diagnostics News: A new study highlights that nearly half of all patients hospitalised for atrial fibrillation (AF) in […]
MoreNews & Trends - Biotechnology
How prepared are we for the next pandemic?
Biotech News: The Melbourne biotechnology community came together for a symposium hosted by BioMelbourne and mRNA Victoria, featuring specialists in […]
MoreNews & Trends - Pharmaceuticals
AbbVie’s JAK inhibitor triumphs: Head-to-Head trial reveals superior outcomes in atopic dermatitis
Pharma News: In a head-to-head trial, AbbVie’s JAK inhibitor Rinvoq (upadacitinib) showed superior efficacy over Regeneron and Sanofi’s Dupixent (dupilumab) […]
More